Professor of Medicine, Brown University
Internal Medicine
Dr. Steven M. Opal, MD
|
|
Give Review
Doctor Steven M. Opal, MD is an expert in the field of Internal Medicine. He researched medicine at Albany Medical College. He received 1 awards: "Regional Top Doctor". Steven Opal is also a published MD. He has 83 publication published. The most recent publication is: PHARMACOLOGICAL SIRT1 ACTIVATION IMPROVES MORTALITY AND MARKEDLY ALTERS TRANSCRIPTIONAL PROFILES THAT ACCOMPANY EXPERIMENTAL SEPSIS. He accepts Medicare.
Publications
- The novel immunotherapeutic oligodeoxynucleotide IMT504 protects neutropenic animals from fatal Pseudomonas aeruginosa bacteremia and sepsis.
- Endothelial barrier dysfunction in septic shock.
- Number needed to treat-to get clinicians' attention*.
- CD28 homodimer interface mimetic peptide acts as a preventive and therapeutic agent in models of severe bacterial sepsis and Gram-negative bacterial peritonitis.
- Immunization of cows with novel core glycolipid vaccine induces anti-endotoxin antibodies in bovine colostrum.
- Evaluation of Imipenem for the Prophylaxis and Therapy of Yersinia pestis Delivered by Aerosol in a Mouse Model of Pneumonic Plague.
- Targeting toll-like receptors 4 intracellular domain to prevent ischemic liver disease: an innovative approach or just a futuristic dream?.
- Dual inhibition of interleukin-1β and interleukin-18: a new treatment option for sepsis?
- The current understanding of sepsis and research priorities for the future.
- The clinical impact of multidrug-resistant gram-negative bacilli in the management of septic shock.
- Sepsis and Scientific Revolutions.
- Over-distension of the airways by mechanical ventilation in the elderly: adding insult to injury.
- Subtyping Clinical Specimens of Influenza A Virus using a Simple Method to Amplify RNA Targets (SMART).
- Recombinant human activated protein C as a therapy for severe sepsis: lessons learned?
- Recurrent Burkholderia gladioli Suppurative Lymphadenitis associated with Neutralizing Anti-IL-12p70 Autoantibodies.
- Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial.
- A peptide antagonist of CD28 signaling attenuates toxic shock and necrotizing soft tissue infection induced by Streptococcus pyogenes.
- Human recombinant lactoferrin for sepsis: too good to be true?*.
- Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock: 2012.
- A Simple Method for Amplifying RNA Targets (SMART).
- Ligation with nucleic Acid sequence-based amplification.
- Novel approaches to the treatment of systemic anthrax.
- Proprotein convertases in health and disease.
- Endotoxemia before and after Surgical Repair for Congenital Heart Disease.
- Immunologic alterations and the pathogenesis of organ failure in the ICU.
- Early in vitro transcription termination in human h5 influenza viral RNA synthesis.
- A matrix metalloprotease-PAR1 system regulates vascular integrity, systemic inflammation and death in sepsis.
- A monoclonal antibody against RAGE alters gene expression and is protective in experimental models of sepsis and pneumococcal pneumonia.
- Biomarkers: the future.
- The evolution of the understanding of sepsis, infection, and the host response: a brief history.
- Inter-α inhibitor proteins: a novel therapeutic strategy for experimental anthrax infection.
- Community acquired pneumonia.
- Estrogen receptor beta agonism increases survival in experimentally induced sepsis and ameliorates the genomic sepsis signature: a pharmacogenomic study.
- Endotoxin desynchronizes biological clocks.
- Ten reasons why we should NOT use severity scores as entry criteria for clinical trials or in our treatment decisions.
- Antibiotic usage and resistance: gaining or losing ground on infections in critically ill patients?
- Molecular biology of inflammation and sepsis: a primer.
- Translational research in the development of novel sepsis therapeutics: logical deductive reasoning or mission impossible?
- Sepsis strategies in development.
- Is the mortality rate for septic shock really decreasing?
- Direct sequence detection of structured h5 influenza viral RNA.
- Sepsis: time to reconsider the concept.
- Host-pathogen interactions in sepsis.
- Communal living by bacteria and the pathogenesis of urinary tract infections.
- Longitudinal studies of inter-alpha inhibitor proteins in severely septic patients: a potential clinical marker and mediator of severe sepsis.
- WAY-202196, a selective estrogen receptor-beta agonist, protects against death in experimental septic shock.
- The duration of hypotension before the initiation of antibiotic treatment is a critical determinant of survival in a murine model of Escherichia coli septic shock: ass...
- Active immunization with a detoxified endotoxin vaccine protects against lethal polymicrobial sepsis: its use with CpG adjuvant and potential mechanisms.
- The activity of pathway-selective estrogen receptor ligands in experimental septic shock.
- The use of immunocompromised animals as models for human septic shock.
- The immunopathogenesis of sepsis in elderly patients.
- Inter-alpha-inhibitor proteins are endogenous furin inhibitors and provide protection against experimental anthrax intoxication.
- Tissue factor pathway inhibitor and antithrombin trial results.
- Intraabdominal infections in infants and children: descriptions and definitions.
- Concept of PIRO as a new conceptual framework to understand sepsis.
- History of U.S. military contributions to the study of vaccines against infectious diseases.
- Insights into severe sepsis in older patients: from epidemiology to evidence-based management.
- Chloroquine enhances survival in Bacillus anthracis intoxication.
- Sepsis associated with immunosuppressive medications: an evidence-based review.
- Coagulation in sepsis.
- Unintended bias, clinical trial results, and the heparin post hoc crossover fallacy.
- Clinical trial design and outcomes in patients with severe sepsis.
- Correlation between mortality and the levels of inter-alpha inhibitors in the plasma of patients with severe sepsis.
- Systemic host responses in severe sepsis analyzed by causative microorganism and treatment effects of drotrecogin alfa (activated).
- A new paradigm for the treatment of sepsis: is it time to consider combination therapy?
- Effect of anti-CD14 monoclonal antibody on clearance of Escherichia coli bacteremia and endotoxemia.
- Corticosteroids for patients with septic shock.
- Orally administered recombinant human interleukin-11 is protective in experimental neutropenic sepsis.
- Endotoxin as a drug target.
- Bioterrorism and physicians.
- Insights into the immune dysfunction associated with thermal injury.
- Antithrombin, heparin, and heparan sulfate.
- The role of interleukin-10 in critical illness.
- Reply to "Generic Statins and Angiotensin Receptor Blockers: Are They Really Useful in Ebola?".
- Microdroplet sandwich real-time rt-PCR for detection of pandemic and seasonal influenza subtypes.
- Year in review 2008: Critical Care--sepsis.
- Coming soon to an ICU near you: severe pandemic influenza in ICU patients in Spain.
- A clinical evaluation committee assessment of recombinant human tissue factor pathway inhibitor (tifacogin) in patients with severe community-acquired pneumonia.
- Bench-to-bedside review: Quorum sensing and the role of cell-to-cell communication during invasive bacterial infection.
- PHARMACOLOGICAL SIRT1 ACTIVATION IMPROVES MORTALITY AND MARKEDLY ALTERS TRANSCRIPTIONAL PROFILES THAT ACCOMPANY EXPERIMENTAL SEPSIS.
- The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3).
- Isolating Influenza RNA from Clinical Samples Using Microfluidic Oil-Water Interfaces.
Schools
Albany Medical College
Fitzsimons Army Med Center
Walter Reed Army Med Center
Doctors Specialties
- Infectious Disease Medicine
- Internal Medicine
Accepted Insurances
Awards
- Regional Top Doctor
Education
-
Albany Medical College
Hospital
-
Rhode Island Hospital
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1902881337 |
| Last Name Of The Provider | OPAL |
| First Name Of The Provider | STEVEN |
| View All |
Similar Doctors
|
|
Dr. Fnu Amrita Rebecca John, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michele Yamamoto, MD |
|
|
Dr. Marguerite A. Neill, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Taro Minami, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Maria V. Fabre, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Aurora E. Pop-Vicas, MD |
|
|
Dr. Hector R. Oshiro, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Muhammad I. Shafi |
|
|
Amrita Desai, MB
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Abdullah Alquadan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Alton J. Curran, MD |
|
|
Dr. Sadia Iftikhar, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Julio C. Defillo, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Aman Nanda, MD
This Doctor is OpenDoctor Recommended.
|